Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Incretin combination therapy: a breakthrough for type 2 diabetes?
  2. Ebola in the DRC: vaccinating in a conflict zone
  3. Next chapter of Ebola preparation begins as Merck’s V920 nears approval
  4. ASH 2018: Celgene’s Revlimid looks set for new approvals in NHL
  5. Breast cancer clinical trials: top drugs under investigation

Latest Content

Incretin combination therapy: a breakthrough for type 2 diabetes?

With unmet needs remaining in type 2 diabetes, pharmaceutical companies are becoming more experimental when developing new treatments. One trend includes combining drugs in one class to determine if they are more efficacious than one drug alone. This trend has been applied to incretins, GLP-1 and GIP, with Eli Lilly recently publishing positive results for its drug candidate LY3298176.

Ebola in the DRC: vaccinating in a conflict zone

Attempts to control the Ebola outbreak in the north-eastern Democratic Republic of Congo have been hindered by ongoing conflict in the area. While Merck’s experimental Ebola vaccine was on the ground within a week of the outbreak being declared, violence and instability in the region is testing the limits of the supply and the effectiveness on vaccination strategies.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top